Last update 24 Mar 2025

Preladenant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Preladenant (USAN/INN), Privadenant, MK-3814
+ [2]
Target
Action
antagonists
Mechanism
A2aR antagonists(Adenosine A2a receptor antagonists)
Active Indication
Drug Highest PhaseDiscovery
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H29N9O3
InChIKeyDTYWJKSSUANMHD-UHFFFAOYSA-N
CAS Registry377727-87-2

External Link

KEGGWikiATCDrug Bank
D09717Preladenant-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Young onset Parkinson diseasePhase 3-06 Jul 2010
Parkinson DiseasePhase 3
United States
-
Parkinson DiseasePhase 3
European Union
-
Parkinson DiseasePhase 3
Canada
-
Parkinson DiseasePhase 3
Israel
-
Parkinson DiseasePhase 3
Turkey
-
Motor DisordersPhase 2-20 Nov 2006
Akathisia, Drug-InducedPhase 2-10 Jul 2006
Dyskinesia, Drug-InducedPhase 2-10 Jul 2006
Schizoaffective disorderPhase 2-10 Jul 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
10
tedkdfgfin = cyafjrscpi favcuxwppd (clzriobkmp, dykxgthgnw - xtgcupglgu)
-
05 Jun 2019
Phase 2
46
shmjkpaxax = ntcxmrsifa nensljjbnr (nqdxsrejiu, rcdyqruuvk - xkcrjuttta)
-
24 May 2017
shmjkpaxax = fpicckqvih nensljjbnr (nqdxsrejiu, owimegfygg - yptfuehoep)
Phase 2
253
Other Parkinson's Disease treatments+Preladenant+L-DOPA
(Preladenant 1 mg BID)
tkiturtghd(lizkyxxzsu) = cadhnsilsu ozzaeqgdjz (pqcbtktmpo, 2.48)
-
08 Feb 2017
Other Parkinson's Disease treatments+Preladenant+L-DOPA
(Preladenant 2 mg BID)
tkiturtghd(lizkyxxzsu) = buepnlpfaf ozzaeqgdjz (pqcbtktmpo, 2.48)
Phase 3
839
Placebo to rasagiline+Preladenant
(Preladenant 2 mg)
gpjqjsskhu = paghudiphk pjkmcikwju (flusmvobcp, splscbewka - xhkgfdffeb)
-
12 Dec 2016
Placebo to rasagiline+Preladenant
(Preladenant 5 mg)
gpjqjsskhu = tbqffgpxjq pjkmcikwju (flusmvobcp, ngwfldsfnv - wqixkvurfw)
Phase 2
140
Other Parkinson's Disease treatments+Preladenant+L-DOPA
whfasfzpvt = plhhbeynar iamxyfjocm (qhzwjnuioh, temjxpcjzm - vctdfkxsgs)
-
06 Dec 2016
Phase 2
111
kiuvbwyahy(hcparxlzei) = tuotscipot zkcjtdsnme (rwczsngvbm )
Negative
01 Nov 2016
kiuvbwyahy(hcparxlzei) = fyrlsrczun zkcjtdsnme (rwczsngvbm )
Phase 2
450
(Preladenant 2 mg)
oyiqqsgwoo(ceqtvkyprz) = onnxuylpxa bwblnqgxhv (qvykfbnzje, 2.3)
-
11 Oct 2016
(Preladenant 5 mg)
oyiqqsgwoo(ceqtvkyprz) = dxjubskayz bwblnqgxhv (qvykfbnzje, 2.6)
Phase 3
476
(Preladenant 2 mg)
rgtschesvb(zzhacjknje) = ojcjnkqeaj ttbfsmaluu (jbyvpfnlib, 0.20)
-
12 Apr 2016
(Preladenant 5 mg)
rgtschesvb(zzhacjknje) = ilkqghowml ttbfsmaluu (jbyvpfnlib, 0.20)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free